A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Inclusion Criteria: * Male or female, 18 to 75 years of age * Body mass index (BMI) ≥30.0 kg/m2, OR BMI ≥27.0 and \<30.0 kg/m2 and previously diagnosed with at least 1 of the following weight-related comorbidities, such as: prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease * At least one self-reported unsuccessful effort to lose body weight Exclusion Criteria: * Prior history/diagnosis/lab evidence of any type of diabetes mellitus (e.g., Type 1, Type 2, gestational), or a history of ketoacidosis or hyperosmolar state * Self-reported body weight change of \>5 kg within 3 months before randomization * Any unbalanced/extreme diets within 3 months of the screening visit, or plan to be on such diets during the study * Current or recent participation in an organized weight reduction program * Current or recent use of any treatment that promotes weight loss or glucose metabolism * Current or recent use of treatment that may cause weight gain * Prior or planned surgical treatment for obesity * Clinically significant or active gastric emptying abnormality, malabsorption, or chronic use of medications that directly affect GI motility * History of chronic pancreatitis or acute pancreatitis within 6 months before screening * Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity * History of major depressive disorder within 2 years of screening, or any history/diag…